Dominiak Katarzyna, Gostyńska-Stawna Aleksandra, Sobczak Agnieszka, Paluszczak Jarosław, Woźniak-Braszak Aneta, Baranowski Mikołaj, Bilski Paweł, Wicher Barbara, Tykarska Ewa, Jelińska Anna, Stawny Maciej
Chair and Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.
Chair and Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Rokietnicka 3, 60-802 Poznan, Poland.
Int J Mol Sci. 2025 Aug 20;26(16):8032. doi: 10.3390/ijms26168032.
Honokiol (HON) and magnolol (MAG), structural isomers from , exhibit notable anticancer activity, particularly against head and neck squamous cell carcinoma (HNSCC). However, due to their high lipophilicity, their intravenous administration is challenging. This study aimed to develop HON- and MAG-loaded intravenous (IV) nanoemulsions using commercial lipid preparations with varying fatty acid compositions. The formulations were physicochemically characterized and evaluated in vitro using FaDu and SCC-040 HNSCC cell lines. HON and MAG were sterilized via ionizing radiation at doses of 25, 100, and 400 kGy. Their suitability for IV use was assessed through PXRD, DSC, TGA, EPR, FT-IR, NMR, and HPLC analyses. All formulations met safety criteria for IV administration, with mean droplet diameters below 241 nm and encapsulation efficiencies exceeding 95%. They significantly reduced cancer cell viability, with a synergistic effect observed in combined HON and MAG formulations compared to single-compound nanoemulsions. Clinoleic-based formulations showed enhanced anticancer efficacy, likely due to the pro-apoptotic properties of oleic acid. Notably, radiation sterilization at the standard 25 kGy dose preserved the thermal, crystalline, and structural stability of HON and MAG, whereas higher doses (400 kGy) induced degradation. Although free radicals were detected via EPR, their transient nature and rapid decay confirmed the method's safety. HON/MAG-loaded nanoemulsions exhibited strong anticancer potential, while radiation sterilization at 25 kGy ensured sterility without compromising stability. These findings provide a preliminary in vitro basis for future in vivo studies investigating HON and MAG as potential adjuvant therapies for HNSCC.
厚朴酚(HON)和和厚朴酚(MAG)是[某种物质]的结构异构体,具有显著的抗癌活性,尤其是对头颈鳞状细胞癌(HNSCC)。然而,由于它们的高亲脂性,静脉给药具有挑战性。本研究旨在使用具有不同脂肪酸组成的商业脂质制剂开发载有HON和MAG的静脉内(IV)纳米乳剂。对制剂进行了物理化学表征,并使用FaDu和SCC - 040 HNSCC细胞系进行了体外评估。HON和MAG通过25、100和400 kGy剂量的电离辐射进行灭菌。通过粉末X射线衍射(PXRD)、差示扫描量热法(DSC)、热重分析(TGA)、电子顺磁共振(EPR)、傅里叶变换红外光谱(FT - IR)、核磁共振(NMR)和高效液相色谱(HPLC)分析评估它们用于静脉注射的适用性。所有制剂均符合静脉给药的安全标准,平均液滴直径低于241 nm,包封率超过95%。它们显著降低了癌细胞活力,与单化合物纳米乳剂相比,在HON和MAG联合制剂中观察到协同效应。基于亚油酸的制剂显示出增强的抗癌功效,这可能归因于油酸的促凋亡特性。值得注意的是,标准25 kGy剂量的辐射灭菌保留了HON和MAG的热、晶体和结构稳定性,而更高剂量(400 kGy)会导致降解。尽管通过EPR检测到了自由基,但它们的短暂性质和快速衰减证实了该方法的安全性。载有HON/MAG的纳米乳剂表现出强大的抗癌潜力,而25 kGy的辐射灭菌确保了无菌性而不影响稳定性。这些发现为未来将HON和MAG作为HNSCC潜在辅助治疗的体内研究提供了初步的体外基础。